Capital Advantage’s Bristol-Myers Squibb BMY Stock Holding History

Capital Advantage’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-3,295	Closed	-$210K	–	79
2017 Q3	$210K	Buy	+3,295	New	+$192K	0.05%	76
2016 Q3	–	Sell	-2,839	Closed	-$209K	–	77
2016 Q2	$209K	Buy	+2,839	New	+$201K	0.06%	73
2015 Q2	–	Sell	-3,965	Closed	-$256K	–	72
2015 Q1	$256K	Hold	3,965	–	–	0.11%	58
2014 Q4	$234K	Hold	3,965	–	–	0.1%	61
2014 Q3	$203K	Buy	+3,965	New	+$198K	0.11%	55

Other funds holding BMY

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Capital Advantage's BMY Position: Q4 2017 in Review

Capital Advantage sold out of Bristol-Myers Squibb (BMY) in Q4 2017, closing a stake of 3,295 shares — an estimated $210K sold.

Capital Advantage first reported a position in BMY in Q3 2014 and held it in 5 quarters. The position peaked at $256K in Q1 2015. 1,735 funds tracked by Wall St. Rank hold BMY as of Q4 2017.

Capital Advantage reported no remaining Bristol-Myers Squibb position as of Q4 2017 after selling out during the quarter.
Capital Advantage sold 3,295 Bristol-Myers Squibb shares in Q4 2017, an estimated $210K.
Capital Advantage first reported a position in Bristol-Myers Squibb in Q3 2014 and held it in 5 quarters.
Capital Advantage's Bristol-Myers Squibb position peaked at $256K in Q1 2015.
1,735 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2017.

Based on Capital Advantage's 13F filing for Q4 2017, filed 13 Feb 2018.